Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.

Nature communications·2026
Same author

Prognostic value of postoperative day 1 prolactin following prolactinoma resection.

Journal of neurosurgery·2026
Same author

IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma.

Cancer research·2026
Same author

Resection versus fenestration for Rathke's cleft cysts: a propensity score-matched analysis of long-term outcomes.

Journal of neurosurgery·2026
Same author

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Molecular biology of pituitary neuroendocrine tumors.

Journal of neuro-oncology·2026

Related Experiment Video

Updated: May 29, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Oncolytic herpes simplex virus engineering and preparation.

Pankaj K Agarwalla1, Manish K Aghi

  • 1Harvard Medical School, Boston, MA, USA.

Methods in Molecular Biology (Clifton, N.J.)
|September 28, 2011
PubMed
Summary
This summary is machine-generated.

Modified herpes simplex virus-1 (HSV-1) shows promise as an oncolytic virus for cancer therapy. Engineering methods and protocols for utilizing these modified viruses are reviewed, highlighting HSV-1

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

  • Virology
  • Oncology
  • Genetic Engineering

Background:

  • Herpes simplex virus-1 (HSV-1) is a double-stranded DNA virus.
  • Modified HSV-1 is explored as an oncolytic virus for various cancers.
  • Conditional replication in tumor cells is a key characteristic of oncolytic viruses.

Purpose of the Study:

  • To review methods for engineering HSV-1 into oncolytic viruses.
  • To describe protocols for the production and purification of engineered HSV-1 oncolytic viruses.

Main Methods:

  • Traditional recombination techniques for HSV-1 modification.
  • Bacterial artificial chromosome (BAC) technology for HSV-1 engineering.
  • Protocols for virus titration, amplification, and purification.

Main Results:

  • HSV-1 offers a large, modifiable genome.
  • Engineered HSV-1 exhibits conditional replication in tumor cells.
  • HSV-1 is sensitive to antiviral agents like ganciclovir and does not integrate into host DNA.

Conclusions:

  • Engineered HSV-1 represents a viable platform for oncolytic virotherapy.
  • Standardized methods for engineering and production are crucial for clinical application.